HPV-FASTER: broadening the scope for prevention of HPV-related cancer.
Identifieur interne : 002323 ( PubMed/Corpus ); précédent : 002322; suivant : 002324HPV-FASTER: broadening the scope for prevention of HPV-related cancer.
Auteurs : F Xavier Bosch ; Claudia Robles ; Mireia Díaz ; Marc Arbyn ; Iacopo Baussano ; Christine Clavel ; Guglielmo Ronco ; Joakim Dillner ; Matti Lehtinen ; Karl-Ulrich Petry ; Mario Poljak ; Susanne K. Kjaer ; Chris J L M. Meijer ; Suzanne M. Garland ; Jorge Salmer N ; Xavier Castellsagué ; Laia Bruni ; Silvia De Sanjosé ; Jack CuzickSource :
- Nature reviews. Clinical oncology [ 1759-4782 ] ; 2016.
English descriptors
- KwdEn :
- Adult, Early Detection of Cancer (methods), Female, Human papillomavirus 16 (immunology), Human papillomavirus 18 (immunology), Humans, Mass Screening (methods), Middle Aged, Papillomavirus Infections (complications), Papillomavirus Infections (prevention & control), Papillomavirus Vaccines (therapeutic use), Sensitivity and Specificity, Uterine Cervical Neoplasms (diagnosis), Uterine Cervical Neoplasms (prevention & control), Uterine Cervical Neoplasms (virology), Vaccination (methods), Vaccination (trends), Young Adult.
- MESH :
- chemical , therapeutic use : Papillomavirus Vaccines.
- complications : Papillomavirus Infections.
- diagnosis : Uterine Cervical Neoplasms.
- immunology : Human papillomavirus 16, Human papillomavirus 18.
- methods : Early Detection of Cancer, Mass Screening, Vaccination.
- prevention & control : Papillomavirus Infections, Uterine Cervical Neoplasms.
- trends : Vaccination.
- virology : Uterine Cervical Neoplasms.
- Adult, Female, Humans, Middle Aged, Sensitivity and Specificity, Young Adult.
Abstract
Human papillomavirus (HPV)-related screening technologies and HPV vaccination offer enormous potential for cancer prevention, notably prevention of cervical cancer. The effectiveness of these approaches is, however, suboptimal owing to limited implementation of screening programmes and restricted indications for HPV vaccination. Trials of HPV vaccination in women aged up to 55 years have shown almost 90% protection from cervical precancer caused by HPV16/18 among HPV16/18-DNA-negative women. We propose extending routine vaccination programmes to women of up to 30 years of age (and to the 45-50-year age groups in some settings), paired with at least one HPV-screening test at age 30 years or older. Expanding the indications for HPV vaccination and much greater use of HPV testing in screening programmes has the potential to accelerate the decline in cervical cancer incidence. Such a combined protocol would represent an attractive approach for many health-care systems, in particular, countries in Central and Eastern Europe, Latin America, Asia, and some more-developed parts of Africa. The role of vaccination in women aged >30 years and the optimal number of HPV-screening tests required in vaccinated women remain important research issues. Cost-effectiveness models will help determine the optimal combination of HPV vaccination and screening in public health programmes, and to estimate the effects of such approaches in different populations.
DOI: 10.1038/nrclinonc.2015.146
PubMed: 26323382
Links to Exploration step
pubmed:26323382Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">HPV-FASTER: broadening the scope for prevention of HPV-related cancer.</title><author><name sortKey="Bosch, F Xavier" sort="Bosch, F Xavier" uniqKey="Bosch F" first="F Xavier" last="Bosch">F Xavier Bosch</name><affiliation><nlm:affiliation>Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia-Catalan Institute of Oncology, IDIBELL, Avenida Gran Via 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Robles, Claudia" sort="Robles, Claudia" uniqKey="Robles C" first="Claudia" last="Robles">Claudia Robles</name><affiliation><nlm:affiliation>Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia-Catalan Institute of Oncology, IDIBELL, Avenida Gran Via 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Diaz, Mireia" sort="Diaz, Mireia" uniqKey="Diaz M" first="Mireia" last="Díaz">Mireia Díaz</name><affiliation><nlm:affiliation>Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia-Catalan Institute of Oncology, IDIBELL, Avenida Gran Via 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Arbyn, Marc" sort="Arbyn, Marc" uniqKey="Arbyn M" first="Marc" last="Arbyn">Marc Arbyn</name><affiliation><nlm:affiliation>Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Baussano, Iacopo" sort="Baussano, Iacopo" uniqKey="Baussano I" first="Iacopo" last="Baussano">Iacopo Baussano</name><affiliation><nlm:affiliation>International Agency for Research on Cancer, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Clavel, Christine" sort="Clavel, Christine" uniqKey="Clavel C" first="Christine" last="Clavel">Christine Clavel</name><affiliation><nlm:affiliation>Centre Hospitalier Universitaire (CHU) Reims, Université de Reims Champagne-Ardenne and Institut National de la Santé et de la Recherche Médicale UMR-S 903, Reims, France.</nlm:affiliation></affiliation></author><author><name sortKey="Ronco, Guglielmo" sort="Ronco, Guglielmo" uniqKey="Ronco G" first="Guglielmo" last="Ronco">Guglielmo Ronco</name><affiliation><nlm:affiliation>Unit of Cancer Epidemiology, Centre for Cancer Prevention (CPO), Torino, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Dillner, Joakim" sort="Dillner, Joakim" uniqKey="Dillner J" first="Joakim" last="Dillner">Joakim Dillner</name><affiliation><nlm:affiliation>Departments of Laboratory Medicine, Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Lehtinen, Matti" sort="Lehtinen, Matti" uniqKey="Lehtinen M" first="Matti" last="Lehtinen">Matti Lehtinen</name><affiliation><nlm:affiliation>University of Tampere, School of Health Sciences, Tampere, Finland.</nlm:affiliation></affiliation></author><author><name sortKey="Petry, Karl Ulrich" sort="Petry, Karl Ulrich" uniqKey="Petry K" first="Karl-Ulrich" last="Petry">Karl-Ulrich Petry</name><affiliation><nlm:affiliation>Department of Obstetrics and Gynaecology, Klinikum Wolfsburg, Wolfsburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Poljak, Mario" sort="Poljak, Mario" uniqKey="Poljak M" first="Mario" last="Poljak">Mario Poljak</name><affiliation><nlm:affiliation>Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.</nlm:affiliation></affiliation></author><author><name sortKey="Kjaer, Susanne K" sort="Kjaer, Susanne K" uniqKey="Kjaer S" first="Susanne K" last="Kjaer">Susanne K. Kjaer</name><affiliation><nlm:affiliation>Virus, Lifestyle &Genes, Danish Cancer Society Research Centre; and Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Meijer, Chris J L M" sort="Meijer, Chris J L M" uniqKey="Meijer C" first="Chris J L M" last="Meijer">Chris J L M. Meijer</name><affiliation><nlm:affiliation>Department of Pathology, VU University Medical Centre (VUmc), Amsterdam, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Garland, Suzanne M" sort="Garland, Suzanne M" uniqKey="Garland S" first="Suzanne M" last="Garland">Suzanne M. Garland</name><affiliation><nlm:affiliation>Department of Microbiology and Infectious Diseases, The Royal Women's Hospital; Murdoch Childrens Research Institute; and Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Salmer N, Jorge" sort="Salmer N, Jorge" uniqKey="Salmer N J" first="Jorge" last="Salmer N">Jorge Salmer N</name><affiliation><nlm:affiliation>Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social, Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.</nlm:affiliation></affiliation></author><author><name sortKey="Castellsague, Xavier" sort="Castellsague, Xavier" uniqKey="Castellsague X" first="Xavier" last="Castellsagué">Xavier Castellsagué</name><affiliation><nlm:affiliation>Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia-Catalan Institute of Oncology, IDIBELL, Avenida Gran Via 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Bruni, Laia" sort="Bruni, Laia" uniqKey="Bruni L" first="Laia" last="Bruni">Laia Bruni</name><affiliation><nlm:affiliation>Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia-Catalan Institute of Oncology, IDIBELL, Avenida Gran Via 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="De Sanjose, Silvia" sort="De Sanjose, Silvia" uniqKey="De Sanjose S" first="Silvia" last="De Sanjosé">Silvia De Sanjosé</name><affiliation><nlm:affiliation>Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia-Catalan Institute of Oncology, IDIBELL, Avenida Gran Via 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Cuzick, Jack" sort="Cuzick, Jack" uniqKey="Cuzick J" first="Jack" last="Cuzick">Jack Cuzick</name><affiliation><nlm:affiliation>Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26323382</idno><idno type="pmid">26323382</idno><idno type="doi">10.1038/nrclinonc.2015.146</idno><idno type="wicri:Area/PubMed/Corpus">002323</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002323</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">HPV-FASTER: broadening the scope for prevention of HPV-related cancer.</title><author><name sortKey="Bosch, F Xavier" sort="Bosch, F Xavier" uniqKey="Bosch F" first="F Xavier" last="Bosch">F Xavier Bosch</name><affiliation><nlm:affiliation>Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia-Catalan Institute of Oncology, IDIBELL, Avenida Gran Via 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Robles, Claudia" sort="Robles, Claudia" uniqKey="Robles C" first="Claudia" last="Robles">Claudia Robles</name><affiliation><nlm:affiliation>Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia-Catalan Institute of Oncology, IDIBELL, Avenida Gran Via 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Diaz, Mireia" sort="Diaz, Mireia" uniqKey="Diaz M" first="Mireia" last="Díaz">Mireia Díaz</name><affiliation><nlm:affiliation>Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia-Catalan Institute of Oncology, IDIBELL, Avenida Gran Via 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Arbyn, Marc" sort="Arbyn, Marc" uniqKey="Arbyn M" first="Marc" last="Arbyn">Marc Arbyn</name><affiliation><nlm:affiliation>Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Baussano, Iacopo" sort="Baussano, Iacopo" uniqKey="Baussano I" first="Iacopo" last="Baussano">Iacopo Baussano</name><affiliation><nlm:affiliation>International Agency for Research on Cancer, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Clavel, Christine" sort="Clavel, Christine" uniqKey="Clavel C" first="Christine" last="Clavel">Christine Clavel</name><affiliation><nlm:affiliation>Centre Hospitalier Universitaire (CHU) Reims, Université de Reims Champagne-Ardenne and Institut National de la Santé et de la Recherche Médicale UMR-S 903, Reims, France.</nlm:affiliation></affiliation></author><author><name sortKey="Ronco, Guglielmo" sort="Ronco, Guglielmo" uniqKey="Ronco G" first="Guglielmo" last="Ronco">Guglielmo Ronco</name><affiliation><nlm:affiliation>Unit of Cancer Epidemiology, Centre for Cancer Prevention (CPO), Torino, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Dillner, Joakim" sort="Dillner, Joakim" uniqKey="Dillner J" first="Joakim" last="Dillner">Joakim Dillner</name><affiliation><nlm:affiliation>Departments of Laboratory Medicine, Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Lehtinen, Matti" sort="Lehtinen, Matti" uniqKey="Lehtinen M" first="Matti" last="Lehtinen">Matti Lehtinen</name><affiliation><nlm:affiliation>University of Tampere, School of Health Sciences, Tampere, Finland.</nlm:affiliation></affiliation></author><author><name sortKey="Petry, Karl Ulrich" sort="Petry, Karl Ulrich" uniqKey="Petry K" first="Karl-Ulrich" last="Petry">Karl-Ulrich Petry</name><affiliation><nlm:affiliation>Department of Obstetrics and Gynaecology, Klinikum Wolfsburg, Wolfsburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Poljak, Mario" sort="Poljak, Mario" uniqKey="Poljak M" first="Mario" last="Poljak">Mario Poljak</name><affiliation><nlm:affiliation>Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.</nlm:affiliation></affiliation></author><author><name sortKey="Kjaer, Susanne K" sort="Kjaer, Susanne K" uniqKey="Kjaer S" first="Susanne K" last="Kjaer">Susanne K. Kjaer</name><affiliation><nlm:affiliation>Virus, Lifestyle &Genes, Danish Cancer Society Research Centre; and Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Meijer, Chris J L M" sort="Meijer, Chris J L M" uniqKey="Meijer C" first="Chris J L M" last="Meijer">Chris J L M. Meijer</name><affiliation><nlm:affiliation>Department of Pathology, VU University Medical Centre (VUmc), Amsterdam, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Garland, Suzanne M" sort="Garland, Suzanne M" uniqKey="Garland S" first="Suzanne M" last="Garland">Suzanne M. Garland</name><affiliation><nlm:affiliation>Department of Microbiology and Infectious Diseases, The Royal Women's Hospital; Murdoch Childrens Research Institute; and Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Salmer N, Jorge" sort="Salmer N, Jorge" uniqKey="Salmer N J" first="Jorge" last="Salmer N">Jorge Salmer N</name><affiliation><nlm:affiliation>Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social, Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.</nlm:affiliation></affiliation></author><author><name sortKey="Castellsague, Xavier" sort="Castellsague, Xavier" uniqKey="Castellsague X" first="Xavier" last="Castellsagué">Xavier Castellsagué</name><affiliation><nlm:affiliation>Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia-Catalan Institute of Oncology, IDIBELL, Avenida Gran Via 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Bruni, Laia" sort="Bruni, Laia" uniqKey="Bruni L" first="Laia" last="Bruni">Laia Bruni</name><affiliation><nlm:affiliation>Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia-Catalan Institute of Oncology, IDIBELL, Avenida Gran Via 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="De Sanjose, Silvia" sort="De Sanjose, Silvia" uniqKey="De Sanjose S" first="Silvia" last="De Sanjosé">Silvia De Sanjosé</name><affiliation><nlm:affiliation>Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia-Catalan Institute of Oncology, IDIBELL, Avenida Gran Via 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Cuzick, Jack" sort="Cuzick, Jack" uniqKey="Cuzick J" first="Jack" last="Cuzick">Jack Cuzick</name><affiliation><nlm:affiliation>Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Nature reviews. Clinical oncology</title><idno type="eISSN">1759-4782</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Early Detection of Cancer (methods)</term><term>Female</term><term>Human papillomavirus 16 (immunology)</term><term>Human papillomavirus 18 (immunology)</term><term>Humans</term><term>Mass Screening (methods)</term><term>Middle Aged</term><term>Papillomavirus Infections (complications)</term><term>Papillomavirus Infections (prevention & control)</term><term>Papillomavirus Vaccines (therapeutic use)</term><term>Sensitivity and Specificity</term><term>Uterine Cervical Neoplasms (diagnosis)</term><term>Uterine Cervical Neoplasms (prevention & control)</term><term>Uterine Cervical Neoplasms (virology)</term><term>Vaccination (methods)</term><term>Vaccination (trends)</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Papillomavirus Vaccines</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Papillomavirus Infections</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Uterine Cervical Neoplasms</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Human papillomavirus 16</term><term>Human papillomavirus 18</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Early Detection of Cancer</term><term>Mass Screening</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Papillomavirus Infections</term><term>Uterine Cervical Neoplasms</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Uterine Cervical Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Sensitivity and Specificity</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Human papillomavirus (HPV)-related screening technologies and HPV vaccination offer enormous potential for cancer prevention, notably prevention of cervical cancer. The effectiveness of these approaches is, however, suboptimal owing to limited implementation of screening programmes and restricted indications for HPV vaccination. Trials of HPV vaccination in women aged up to 55 years have shown almost 90% protection from cervical precancer caused by HPV16/18 among HPV16/18-DNA-negative women. We propose extending routine vaccination programmes to women of up to 30 years of age (and to the 45-50-year age groups in some settings), paired with at least one HPV-screening test at age 30 years or older. Expanding the indications for HPV vaccination and much greater use of HPV testing in screening programmes has the potential to accelerate the decline in cervical cancer incidence. Such a combined protocol would represent an attractive approach for many health-care systems, in particular, countries in Central and Eastern Europe, Latin America, Asia, and some more-developed parts of Africa. The role of vaccination in women aged >30 years and the optimal number of HPV-screening tests required in vaccinated women remain important research issues. Cost-effectiveness models will help determine the optimal combination of HPV vaccination and screening in public health programmes, and to estimate the effects of such approaches in different populations.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26323382</PMID><DateCreated><Year>2016</Year><Month>01</Month><Day>25</Day></DateCreated><DateCompleted><Year>2016</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2017</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-4782</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>2</Issue><PubDate><Year>2016</Year><Month>02</Month></PubDate></JournalIssue><Title>Nature reviews. Clinical oncology</Title><ISOAbbreviation>Nat Rev Clin Oncol</ISOAbbreviation></Journal><ArticleTitle>HPV-FASTER: broadening the scope for prevention of HPV-related cancer.</ArticleTitle><Pagination><MedlinePgn>119-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nrclinonc.2015.146</ELocationID><Abstract><AbstractText>Human papillomavirus (HPV)-related screening technologies and HPV vaccination offer enormous potential for cancer prevention, notably prevention of cervical cancer. The effectiveness of these approaches is, however, suboptimal owing to limited implementation of screening programmes and restricted indications for HPV vaccination. Trials of HPV vaccination in women aged up to 55 years have shown almost 90% protection from cervical precancer caused by HPV16/18 among HPV16/18-DNA-negative women. We propose extending routine vaccination programmes to women of up to 30 years of age (and to the 45-50-year age groups in some settings), paired with at least one HPV-screening test at age 30 years or older. Expanding the indications for HPV vaccination and much greater use of HPV testing in screening programmes has the potential to accelerate the decline in cervical cancer incidence. Such a combined protocol would represent an attractive approach for many health-care systems, in particular, countries in Central and Eastern Europe, Latin America, Asia, and some more-developed parts of Africa. The role of vaccination in women aged >30 years and the optimal number of HPV-screening tests required in vaccinated women remain important research issues. Cost-effectiveness models will help determine the optimal combination of HPV vaccination and screening in public health programmes, and to estimate the effects of such approaches in different populations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bosch</LastName><ForeName>F Xavier</ForeName><Initials>FX</Initials><AffiliationInfo><Affiliation>Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia-Catalan Institute of Oncology, IDIBELL, Avenida Gran Via 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robles</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia-Catalan Institute of Oncology, IDIBELL, Avenida Gran Via 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Díaz</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia-Catalan Institute of Oncology, IDIBELL, Avenida Gran Via 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arbyn</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baussano</LastName><ForeName>Iacopo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>International Agency for Research on Cancer, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clavel</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire (CHU) Reims, Université de Reims Champagne-Ardenne and Institut National de la Santé et de la Recherche Médicale UMR-S 903, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ronco</LastName><ForeName>Guglielmo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Unit of Cancer Epidemiology, Centre for Cancer Prevention (CPO), Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dillner</LastName><ForeName>Joakim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departments of Laboratory Medicine, Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehtinen</LastName><ForeName>Matti</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Tampere, School of Health Sciences, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petry</LastName><ForeName>Karl-Ulrich</ForeName><Initials>KU</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynaecology, Klinikum Wolfsburg, Wolfsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poljak</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kjaer</LastName><ForeName>Susanne K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Virus, Lifestyle &Genes, Danish Cancer Society Research Centre; and Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meijer</LastName><ForeName>Chris J L M</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, VU University Medical Centre (VUmc), Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garland</LastName><ForeName>Suzanne M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Infectious Diseases, The Royal Women's Hospital; Murdoch Childrens Research Institute; and Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salmerón</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social, Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castellsagué</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia-Catalan Institute of Oncology, IDIBELL, Avenida Gran Via 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruni</LastName><ForeName>Laia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia-Catalan Institute of Oncology, IDIBELL, Avenida Gran Via 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Sanjosé</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia-Catalan Institute of Oncology, IDIBELL, Avenida Gran Via 199-203, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuzick</LastName><ForeName>Jack</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>C569/A16891</GrantID><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Clin Oncol</MedlineTA><NlmUniqueID>101500077</NlmUniqueID><ISSNLinking>1759-4774</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053918">Papillomavirus Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>BJOG. 2008 Jul;115(8):947-56</RefSource><PMID Version="1">18503574</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Feb 19;372(8):711-23</RefSource><PMID Version="1">25693011</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2013 Aug 20;31(37):3962-71</RefSource><PMID Version="1">23777952</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2011 Dec;121(12):4593-9</RefSource><PMID Version="1">22133884</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2014 Oct;14(10):958-66</RefSource><PMID Version="1">25107680</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2013 Dec 17;32(1):26-32</RefSource><PMID Version="1">24211166</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2012 Jul 10;107(2):243-54</RefSource><PMID Version="1">22699825</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Clin Oncol. 2013 Jul;10(7):400-10</RefSource><PMID Version="1">23736648</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Virol. 2014 May;60(1):44-9</RefSource><PMID Version="1">24630483</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Open Virol J. 2012;6:198-203</RefSource><PMID Version="1">23341855</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Milbank Q. 2012 Mar;90(1):5-37</RefSource><PMID Version="1">22428690</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Prev Med. 2010 Dec;39(6):559-63</RefSource><PMID Version="1">21084077</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Salud Publica Mex. 2003;45 Suppl 3:S449-62</RefSource><PMID Version="1">14746039</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2010 Nov;11(11):1048-56</RefSource><PMID Version="1">20952254</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2009 Apr 2;360(14):1385-94</RefSource><PMID Version="1">19339719</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ. 2008 Sep 18;337:a1284</RefSource><PMID Version="1">18801868</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2008 May;9(5):425-34</RefSource><PMID Version="1">18407790</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2010 Dec;10(12):862-74</RefSource><PMID Version="1">21075056</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 2013 Aug;130(2):264-8</RefSource><PMID Version="1">23623831</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2011 Nov 8;29(48):8929-36</RefSource><PMID Version="1">21945961</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013 Sep 26;8(9):e75552</RefSource><PMID Version="1">24086567</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2012 Nov 20;30 Suppl 5:F183-91</RefSource><PMID Version="1">23199962</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Treat Rev. 2006 Nov;32(7):516-23</RefSource><PMID Version="1">17008015</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2011 Aug 1;204(3):377-84</RefSource><PMID Version="1">21742836</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Technol Assess Health Care. 2010 Apr;26(2):183-91</RefSource><PMID Version="1">20392322</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2007 Aug 15;298(7):743-53</RefSource><PMID Version="1">17699008</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2010 Oct 6;102(19):1478-88</RefSource><PMID Version="1">20841605</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Aust N Z J Public Health. 2007 Jun;31(3):235-42</RefSource><PMID Version="1">17679241</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2014 Feb;15(2):172-83</RefSource><PMID Version="1">24433684</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2014 May;25(5):927-35</RefSource><PMID Version="1">24445150</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Oncol. 2014 Apr;21(2):e255-64</RefSource><PMID Version="1">24764711</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2012 Nov 20;30 Suppl 5:F107-16</RefSource><PMID Version="1">23199953</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ. 2014 Sep 16;349:g5264</RefSource><PMID Version="1">25232064</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Microbiol Infect. 2015 Sep;21(9):817-26</RefSource><PMID Version="1">25936581</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2008 Oct 16;26(44):5654-61</RefSource><PMID Version="1">18723068</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2005 Nov 2;294(17):2173-81</RefSource><PMID Version="1">16264158</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2009 Jul;10 (7):672-82</RefSource><PMID Version="1">19540162</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Epidemiol Biomarkers Prev. 2013 Jul;22(7):1313-8</RefSource><PMID Version="1">23632816</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2015 Mar 3;33(10):1284-90</RefSource><PMID Version="1">25593103</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Value Health. 2009 Jul-Aug;12(5):697-707</RefSource><PMID Version="1">19490561</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2014 Feb 8;383(9916):524-32</RefSource><PMID Version="1">24192252</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2007 Apr;8(4):311-6</RefSource><PMID Version="1">17395104</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Virol. 2014 Dec;61(4):553-7</RefSource><PMID Version="1">25453572</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2001 Apr 12;344(15):1125-31</RefSource><PMID Version="1">11297703</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ. 2008 Jul 17;337:a769</RefSource><PMID Version="1">18640957</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2014 Aug 15;210(4):517-34</RefSource><PMID Version="1">24610876</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1995 Jun 17;345(8964):1533-6</RefSource><PMID Version="1">7791438</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Public Health. 2011 Apr;56(2):153-62</RefSource><PMID Version="1">21110060</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2012 Nov 20;30 Suppl 5:F12-23</RefSource><PMID Version="1">23199955</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biopharm Stat. 2013;23(6):1228-48</RefSource><PMID Version="1">24138429</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2008 Oct;9(10):937-45</RefSource><PMID Version="1">18783988</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Med Econ. 2010 Mar;13(1):110-8</RefSource><PMID Version="1">20085477</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2014 Mar;15(3):315-22</RefSource><PMID Version="1">24529697</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 2009 Dec;115(3 Suppl):S1-6</RefSource><PMID Version="1">19217149</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 2009 Oct 20;151(8):538-45</RefSource><PMID Version="1">19841455</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Ther. 2014 Jan 1;36(1):17-23</RefSource><PMID Version="1">24417782</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2008 May 15;122(10 ):2294-300</RefSource><PMID Version="1">18240149</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Wkly Epidemiol Rec. 2014 Oct 24;89(43):465-91</RefSource><PMID Version="1">25346960</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2013 Nov;133(9):2253-8</RefSource><PMID Version="1">23616200</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ. 2015 Jan 06;350:g7584</RefSource><PMID Version="1">25567037</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014 Mar 20;9(3):e89974</RefSource><PMID Version="1">24651645</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2014 Jun 15;134(12):2891-901</RefSource><PMID Version="1">24248915</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2011 Jun 6;29(25):4238-43</RefSource><PMID Version="1">21473953</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2014 Jan;11(1):e1001585</RefSource><PMID Version="1">24453946</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2013 Sep 15;133(6):1459-69</RefSource><PMID Version="1">23463194</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2015 Mar 30;33(14):1673-81</RefSource><PMID Version="1">25720792</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Jan;13(1):89-99</RefSource><PMID Version="1">22075171</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2012 Nov 20;30 Suppl 5:F88-99</RefSource><PMID Version="1">23199969</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Clin Pathol. 2015 Jan;143(1):126-33</RefSource><PMID Version="1">25511151</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Opin Drug Saf. 2015 May;14(5):697-712</RefSource><PMID Version="1">25689872</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2015 May;15(5):565-80</RefSource><PMID Version="1">25744474</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2006 Aug 31;24 Suppl 3:S3/171-7</RefSource><PMID Version="1">16844268</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2013 Oct;49(15):3262-73</RefSource><PMID Version="1">23751569</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2012 Nov 20;30 Suppl 5:F139-48</RefSource><PMID Version="1">23199957</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2010 Mar;11(3):249-57</RefSource><PMID Version="1">20089449</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Salud Publica Mex. 2010 Nov-Dec;52(6):544-59</RefSource><PMID Version="1">21271014</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2008 Aug 21;359(8):821-32</RefSource><PMID Version="1">18716299</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2010 Dec 15;202(12):1789-99</RefSource><PMID Version="1">21067372</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2014 Nov;50(16):2846-54</RefSource><PMID Version="1">25155250</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2010 Nov 1;70(21):8569-77</RefSource><PMID Version="1">20978200</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2010 Nov 3;102(21):1653-62</RefSource><PMID Version="1">20944077</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Oct 27;365(17):1576-85</RefSource><PMID Version="1">22029979</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2014 Jul 1;135(1):204-13</RefSource><PMID Version="1">24347441</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2015 May 15;136(10):2361-8</RefSource><PMID Version="1">25345358</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Med Res. 2009 Aug;40(6):478-85</RefSource><PMID Version="1">19853188</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Microbiol. 2015 Jan;53(1):52-9</RefSource><PMID Version="1">25339396</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2007 Oct 18;357(16):1589-97</RefSource><PMID Version="1">17942872</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013 Jul 17;8(7):e68329</RefSource><PMID Version="1">23873171</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sex Transm Infect. 2006 Apr;82(2):169-74</RefSource><PMID Version="1">16581749</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 2011 Jun 1;121(3):505-9</RefSource><PMID Version="1">21420158</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Jan;13(1):78-88</RefSource><PMID Version="1">22177579</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Gynecol Obstet. 2015 Jul;292(1):197-205</RefSource><PMID Version="1">25588329</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2013 Nov;49(16):3450-61</RefSource><PMID Version="1">23886586</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Med. 2013 Oct 22;11:227</RefSource><PMID Version="1">24148310</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2012 Nov 20;30 Suppl 5:F123-38</RefSource><PMID Version="1">23199956</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2011 Jun 28;105(1):28-37</RefSource><PMID Version="1">21629249</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25</RefSource><PMID Version="1">16949997</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2014 Apr 15;134(8):1835-43</RefSource><PMID Version="1">24122508</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Obstet Gynecol Scand. 2011 May;90(5):445-51</RefSource><PMID Version="1">21306349</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2010 Mar 3;102(5):315-24</RefSource><PMID Version="1">20157096</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Feb 3;364(5):401-11</RefSource><PMID Version="1">21288094</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2012 Nov 15;131(10):2349-59</RefSource><PMID Version="1">22323075</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2015 Jan 1;136(1):98-107</RefSource><PMID Version="1">24817381</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2014 Dec 20;384(9961):2213-27</RefSource><PMID Version="1">25189358</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Rev Pharmacoecon Outcomes Res. 2008 Oct;8(5):491-500</RefSource><PMID Version="1">20528334</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2015 Mar 24;33(13):1556-61</RefSource><PMID Version="1">25701671</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2014 Jul 1;135(1):109-16</RefSource><PMID Version="1">24615258</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2013 Oct 15;133(8):1876-81</RefSource><PMID Version="1">23564420</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23</RefSource><PMID Version="1">19903804</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Epidemiol Prev. 2012 May-Aug;36(3-4 Suppl 1):e1-72</RefSource><PMID Version="1">22828243</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2006 Aug 31;24 Suppl 3:S3/90-7</RefSource><PMID Version="1">16950022</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2014 Aug 26;111(5):965-9</RefSource><PMID Version="1">24992581</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2009 Jun 6;373(9679):1949-57</RefSource><PMID Version="1">19493565</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2014 Mar;106(3):djt460</RefSource><PMID Version="1">24552678</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Infect Agent Cancer. 2014 Jan 20;9(1):4</RefSource><PMID Version="1">24438317</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24</RefSource><PMID Version="1">17380109</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2013 Dec 31;31 Suppl 7:H80-2</RefSource><PMID Version="1">24332300</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2015 Mar 24;33(13):1608-13</RefSource><PMID Version="1">25681664</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2008 Aug 19;26 Suppl 10:K76-86</RefSource><PMID Version="1">18847560</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2006 Feb 11;367(9509):489-98</RefSource><PMID Version="1">16473126</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Obstet Gynecol. 2015 Feb;125(2):330-7</RefSource><PMID Version="1">25569009</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055088" MajorTopicYN="N">Early Detection of Cancer</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052162" MajorTopicYN="N">Human papillomavirus 16</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052161" MajorTopicYN="N">Human papillomavirus 18</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030361" MajorTopicYN="N">Papillomavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053918" MajorTopicYN="N">Papillomavirus Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26323382</ArticleId><ArticleId IdType="pii">nrclinonc.2015.146</ArticleId><ArticleId IdType="doi">10.1038/nrclinonc.2015.146</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002323 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002323 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26323382
|texte= HPV-FASTER: broadening the scope for prevention of HPV-related cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26323382" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |